Ana Tesi-Rocha, MD

Neuromuscular neurologist, Pediatric neurologist

Clinical Assistant Professor, Neurology & Neurological Sciences

Neuromuscular Program

  • 211 Quarry Road
  • Palo Alto, CA 94304
  • Phone: 650-723-6469
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Board Certification: Pediatric Neurology, American Board of Psychiatry and Neurology (2010)

Fellowship: Children's National Medical Center (2010) DC

Internship: Georgetown University Hospital (2007) DC

Residency: Hospital Nacional de Pediatria Juan P Garrahan (2001) Argentina

Residency: Alejandro Posadas Hospital (1997) Argentina

Medical Education: Universidad de Buenos Aires (1994)

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

COOPERATIVE INTERNATIONAL NEUROMUSCULAR RESEARCH GROUP DUCHENNE NATURAL HISTORY STUDY DEMONSTRATES INSUFFICIENT DIAGNOSIS AND TREATMENT OF CARDIOMYOPATHY IN DUCHENNE MUSCULAR DYSTROPHY
Spurney, C., Shimizu, R., Morgenroth, L. P., Kolski, H., Gordish-Dressman, H., & Clemens, P. R. (2014). COOPERATIVE INTERNATIONAL NEUROMUSCULAR RESEARCH GROUP DUCHENNE NATURAL HISTORY STUDY DEMONSTRATES INSUFFICIENT DIAGNOSIS AND TREATMENT OF CARDIOMYOPATHY IN DUCHENNE MUSCULAR DYSTROPHY. MUSCLE & NERVE, 50(2), 250-256.

Novel large deletion in the ACTA1 gene in a child with autosomal recessive nemaline myopathy
Friedman, B., Simpson, K., Tesi-Rocha, C., Zhou, D., Palmer, C. A., & Suchy, S. F. (2014). Novel large deletion in the ACTA1 gene in a child with autosomal recessive nemaline myopathy. NEUROMUSCULAR DISORDERS, 24(4), 331-334.

'Double trouble': diagnostic challenges in Duchenne muscular dystrophy in patients with an additional hereditary skeletal dysplasia.
Donkervoort, S., Schindler, A., Tesi-Rocha, C., Schreiber, A., Leach, M. E., & Bönnemann, C. G. (2013). 'Double trouble': diagnostic challenges in Duchenne muscular dystrophy in patients with an additional hereditary skeletal dysplasia. Neuromuscular disorders , 23(12), 955-961.

The cooperative international neuromuscular research group Duchenne natural history study: Glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures
Henricson, E. K., Abresch, R. T., Cnaan, A., Hu, F., Duong, T., & McDonald, C. M. (2013). The cooperative international neuromuscular research group Duchenne natural history study: Glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. MUSCLE & NERVE, 48(1), 55-67.

Pentoxifylline as a rescue treatment for DMD A randomized double-blind clinical trial
Escolar, D. M., Zimmerman, A., Bertorini, T., Clemens, P. R., Connolly, A. M., & Mah, J. K. (2012). Pentoxifylline as a rescue treatment for DMD A randomized double-blind clinical trial. NEUROLOGY, 78(12), 904-913.

LIQUID FORMULATION OF PENTOXIFYLLINE IS A POORLY TOLERATED TREATMENT FOR DUCHENNE DYSTROPHY
Zimmerman, A., Clemens, P. R., Tesi-Rocha, C., Connolly, A., Iannaccone, S. T., & Escolar, D. M. (2011). LIQUID FORMULATION OF PENTOXIFYLLINE IS A POORLY TOLERATED TREATMENT FOR DUCHENNE DYSTROPHY. MUSCLE & NERVE, 44(2), 170-173.

SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy
Pegoraro, E., Hoffman, E. P., Piva, L., Gavassini, B. F., Cagnin, S., & McDonald, C. M. (2011). SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. NEUROLOGY, 76(3), 219-226.

Limb-Girdle and Congenital Muscular Dystrophies: Current Diagnostics, Management, and Emerging Technologies
Rocha, C. T., & Hoffman, E. P. (2010). Limb-Girdle and Congenital Muscular Dystrophies: Current Diagnostics, Management, and Emerging Technologies. CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 10(4), 267-276.

PPAR alpha L162V underlies variation in serum triglycerides and subcutaneous fat volume in young males
Uthurralt, J., Gordish-Dressman, H., Bradbury, M., Tesi-Rocha, C., Devaney, J., & Hoffman, E. P. (2007). PPAR alpha L162V underlies variation in serum triglycerides and subcutaneous fat volume in young males. BMC MEDICAL GENETICS, 8.

CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy
Escolar, D. M., Buyse, G., Henricson, E., Leshner, R., Florence, J., & Wessel, H. (2005). CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. ANNALS OF NEUROLOGY, 58(1), 151-155.

Update on diagnosis and treatment of hereditary and acquired polyneuropathies in childhood.
Rocha, C. T., & Escolar, D. M. (2004). Update on diagnosis and treatment of hereditary and acquired polyneuropathies in childhood. Supplements to Clinical neurophysiology, 57, 255-271.

Drop episodes in Coffin-Lowry syndrome: an unusual type of startle response
Caraballo, R., Rocha, A. T., Medina, C., & Fejerman, N. (2000). Drop episodes in Coffin-Lowry syndrome: an unusual type of startle response. EPILEPTIC DISORDERS, 2(3), 173-176.